Abstract
Abstract
Purpose of Review
The purpose of this review is to investigate the use of digital health technologies and/or digital therapeutics (DTx) products in the treatment of substance use disorders (SUDs) in the general population and among criminal justice–involved individuals.
Recent Findings
Despite an expanding evidence base, only three SUD DTxs have received federal regulatory approval. Across studies, DTx products have proven successful in engaging patients in SUD treatment and reducing healthcare costs and resource utilizations. Findings for emerging SUD DTx products show similar results. Still, there is a paucity of evidence regarding the use of digital health technologies and/or DTx among criminal justice populations.
Summary
DTxs have proven effective for treating multiple SUD types (e.g., nicotine and opioids) among the general population. DTx shows similar promise among justice-involved populations, but additional efficacy and implementation research is needed to address barriers such as cost, cultural resistance, and infrastructure.
Funder
National Institute on Drug Abuse
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Clinical Psychology
Reference108 articles.
1. Glucobit Inc. Reframe: quit or cut back on drinking, build healthier drinking habits. 2022. Reframe App website: https://www.reframeapp.com. Accessed 18 Feb 2023.
2. HereNOW Help, Inc. HereNOW Connect. 2021. https://play.google.com/store/apps/details?id=com.herenowhelp.rehab.client&hl=en_US&gl=US. Accessed 18 Feb 2023.
3. Hong JS, Wasden C, Han DH. Introduction of digital therapeutics. Comput Methods Programs Biomed. 2021. https://doi.org/10.1016/j.cmpb.2021.106319.
4. Wright W. Digital therapeutics and FDA regulations. Pearl Pathways, 2022. https://www.pearlpathways.com/digital-therapeutics-and-fda-regulations/. Accessed 15 Aug 2023.
5. Wang C, Lee C, Shin H. Digital therapeutics from bench to bedside. NPJ Digit Med. 2023;6:38. https://doi.org/10.1038/s41746-023-00777-z.